As of today (2024-04-23), Avadel Pharmaceuticals's share price is $18.09. Avadel Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.79. Hence, Avadel Pharmaceuticals's Price to Tangible Book Ratio of today is 22.93.
The historical rank and industry rank for Avadel Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
AVDL'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.68 Med: 14.47 Max: 577.22
Current: 22.9
During the past 13 years, Avadel Pharmaceuticals's highest Price to Tangible Book Ratio was 577.22. The lowest was 2.68. And the median was 14.47.
AVDL's Price-to-Tangible-Book is ranked worse than 95.99% of 872
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs AVDL: 22.90
A closely related ratio is called PB Ratio. As of today, Avadel Pharmaceuticals's share price is $18.09. Avadel Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.98. Hence, Avadel Pharmaceuticals's P/B Ratio of today is 18.53.
Avadel Pharmaceuticals Price-to-Tangible-Book Historical Data
The historical data trend for Avadel Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avadel Pharmaceuticals Price-to-Tangible-Book Distribution
For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Avadel Pharmaceuticals's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Avadel Pharmaceuticals Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Avadel Pharmaceuticals (Avadel Pharmaceuticals) Business Description
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVDL has been successfully added to your 